Basic Information
Dzuveo
Regulatory Information
EMEA/H/C/004335
Authorised
June 25, 2018
April 26, 2018
8
September 12, 2024
Company Information
France
Laboratoire Aguettant 1, rue Alexander Fleming 69007 Lyon
Laboratoire Aguettant
Active Substances Detail
EMA Resources
Detailed Information
Therapeutic Indication
### Therapeutic indication Dzuveo is indicated for the management of acute moderate to severe pain in adult patients.
Overview Summary
Dzuveo is an opioid pain medicine used to treat moderate to severe pain in adults. It is a ‘hybrid medicine’. This means that it is similar to a ‘reference medicine’ (called Sufenta Forte) containing the same active substance. The difference between the products is that Dzuveo is available as sublingual tablets (tablets to be dissolved under the tongue) while the reference medicine is a solution for injection. Dzuveo contains the active substance sufentanil.